Open for inclusion

A phase 1/2 study of combination of pixantrone, etoposide, bendamustine and in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T- cell phenotype- The P(RE)BEN study

Cancer type: Lymphoma

Phase: I/II

Principal Investigator: Leppä Sirpa

Country: FI

Keywords: Finland, Helsinki

Status: Open for inclusion

Link to